Home   >  
MAPK Pathway
  >  
Raf

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Raf

Chemical Structure Cat. No. Product Name CAS No.
KG5 Chemical Structure
 BCP46930 KG5 877874-85-6
KG 5 is an orally available PDGFRß and B-Raf allosteric inhibitor.
Encorafenib Chemical Structure
 BCP44104 Encorafenib 1269440-29-0
Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.
Rineterkib hydrochloride Chemical Structure
 BCP43938 Rineterkib hydrochloride 1715025-34-5
Rineterkib is a RAF and ERK1/2 inhibitor which has demonstrated preclinical activity in multiple MAPK activated cancer cells and xenograft models.
MCP110 Chemical Structure
 BCP43521 MCP110 521310-51-0
MCP110 is an inhibitor of Ras.
Vemurafenib Chemical Structure
 BCP43160 Vemurafenib 1029872-54-5
Vemurafenib is a selective inhibitor of BRAF kinase that is used in the therapy of patients with metastatic and advanced malignant melanoma. Vemurafenib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe cases of clinically apparent acute liver injury.
Lifirafenib Chemical Structure
 BCP42783 Lifirafenib 1446090-79-4
Lifirafenib is a Novel potent and selective RAF Kinase and EGFR inhibitor.
Rineterkib Chemical Structure
 BCP38204 Rineterkib 1715025-32-3
Rineterkib is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway.
Donafenib Chemical Structure
 BCP34023 Donafenib 1130115-44-4
Donafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).
AZ304 Chemical Structure
 BCP31900 AZ304 942507-42-8
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity.
Belvarafenib Chemical Structure
 BCP31233 Belvarafenib 1446113-23-0
Belvarafenib is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
123下一页末页共 49 条记录 1 / 5 页 
0086-13720134139